Status:
COMPLETED
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
Lead Sponsor:
Bausch & Lomb Incorporated
Conditions:
Bacterial Conjunctivitis
Eligibility:
All Genders
1+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was c...
Eligibility Criteria
Inclusion
- Subjects who are at least one year of age.
- Subjects who have a clinical diagnosis of acute bacterial conjunctivitis.
- Subjects who are willing to discontinue contact lens wear for the duration of the study.
Exclusion
- Subjects who have any uncontrolled systemic disease or debilitating disease.
- Subjects with known sensitivity or contraindications to besifloxacin, fluoroquinolones or any ingredients in study drugs.
- Subjects who are expected to require treatment with any disallowed medications.
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
474 Patients enrolled
Trial Details
Trial ID
NCT00972777
Start Date
October 1 2009
End Date
February 1 2011
Last Update
March 29 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bausch & Lomb Incorporated
Rochester, New York, United States, 14609